Podcasts

E-Books

Videos

Articles

Business & Practice

Tony Hagen is senior managing editor for The Center for Biosimilars

A supply chain shortage of Avastin (bevacizumab) is prompting policies for use of bevacizumab biosimilars instead, which the American Academy of Ophthalmology says could lead to problems.

Ophthalmology Group Opposes Payer Recommendations for Bevacizumab Biosimilars

When it comes to exports, Celltrion Healthcare leads the way among Republic of Korea pharmaceuticals producers. The company's biosimilars are the leading exports.

Celltrion Dominates Republic of Korea Drug Exports, Targets Latin America

After much anticipation, the FDA approves the first interchangeable biosimilar, which is hoped to bring down the high cost of insulin.

FDA Approves Semglee Insulin Glargine as First Interchangeable Biosimilar

In part 1 of this interview, Cate Lockhart, executive director of the Biologics and Biosimilar Collective Intelligence Consortium, details some of her expectations for further growth of the US biosimilar market.

Cate Lockhart: Is There Hope for a Robust Biosimilar Industry in the United States?

Sarfaraz K. Niazi, PhD, is an adjunct professor of biopharmaceutical sciences at the University of Illinois and the University of Houston, and founder of biosimilars companies Karyo Biologics and Adello Biologics. He also founded the biosimilar advisory company PharmSci.

Sarfaraz K. Niazi, PhD, a member of The Center for Biosimilars® Advisory Board, recounts a debate with a young clinician over the reliability of biosimilarity testing. 

Column: A Biosimilars Dialogue With a Young Clinician

Kenneth Komorny, PharmD, BCPS, was a co-lead on development of National Comprehensive Cancer Network (NCCN) recommendations for biosimilar management. He explains some of the positions the NCCN has taken.

Moffitt Chief Pharmacy Officer Discusses NCCN Biosimilar Recommendations

Sonia T. Oskouei, PharmD, BCMAS, DPLA, vice president of Biosimilars at Cardinal Health, discusses motivating factors that affect use of biosimilars in oncology.

Oncologists' Cost Sensitivity May Drive Biosimilar Uptake

Minnesota legislators introduce what could possibly become the first law to curtail payers' rights to determine which biologics patients have access to.

Minnesota Moves to Override Payer Preferences on Biosimilars

Investigators evaluated trial spending and reasons for biologics license application failures. 

Study: Biosimilar vs Originator Spending on Comparative Efficacy Trials

Anar Dossa, director of Pharmacy Services at Pacific Blue Cross, discusses the company's involvement with British Columbia's biosimilars switching program.

Practice